MPLT · MapLight Therapeutics, Inc.
$9.41
-0.41 (-4.18%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$485.11M
Shares
46.38M
Volume · Oct 5
262.15K
Avg daily vol (3M)
861.58K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.82
Open$9.70
Day$9.43–10.17
Available close range$9.63–39.80
Avg vol 30d560K
Short int3.3M · 7.1% float · 6.1d
Short vol68%
Last earningsJul 27, 2026
DataOct 2025–Oct 2026
Filing10-Q · Aug 13
The closing range uses available history since Oct 27, 2025; less than a full year is stored.
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$229.83M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.2
Trailing earnings · reciprocal yield 480.9%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$304.73M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5,854.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
7.1%
Latest settlement · 6.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−54%
below
Price vs 50-day avg
−22%
below
RSI (14)
28
oversold
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−25%
trailing
6-month return
−63%
trailing
YTD return
−44%
this year
Relative strength
−75%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $22 — 200d above 50d
Institutional flow
Accumulating
+31% holders QoQ · +37 funds added
Insider flow
Accumulating
Net +$58.8M over 90 days · 60% sells
Short interest
Falling
7.11% of float · ▼ -3.8% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
106 holders — 13F breadth
Squeeze score
49
elevated · 0–100
Fundamentals
EPS growth
+82%
Y/Y
Free cash flow
$-138.6M
Quant / Vol
risk profile
Volatility
116%
annualized · 1-yr
Max drawdown
−76%
past year
ATR
8.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−54%
Bearish
Price vs 50-day avg
−22%
Bearish
RSI (14)
28
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $13 › 200d $22 — 200d above 50d
Institutional flow
Accumulating
+31% holders QoQ · +37 funds added
Insider flow
Accumulating
Net +$58.8M over 90 days · 60% sells
Short interest
Falling
7.11% of float · ▼ -3.8% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
106 holders — 13F breadth
Price context
position in its available closing range
Range low $10
Now $10 · 1%
Range high $40
vs 200-day avg -54%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and investments | $351.3M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MPLT
this stock
MapLight Therapeutics, Inc.
|
$485.11M | -44.1% | — | — | 7.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MPLT | -6.1% | -25.3% | -62.7% | -3.6% | -44.1% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -5.9% | -24.8% | -74.9% | -4.6% | -57.0% |